Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) and X4 Pharmaceuticals (NASDAQ:XFOR)
BioCryst Pharmaceuticals (NASDAQ:BCRX) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.
Earnings and Valuation
This table compares BioCryst Pharmaceuticals and X4 Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BioCryst Pharmaceuticals||$48.83 million||15.89||-$108.90 million||($0.94)||-5.35|
|X4 Pharmaceuticals||N/A||N/A||-$52.81 million||($4.63)||-1.89|
Risk & Volatility
BioCryst Pharmaceuticals has a beta of 2.78, suggesting that its stock price is 178% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.
This table compares BioCryst Pharmaceuticals and X4 Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
89.0% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 68.5% of X4 Pharmaceuticals shares are held by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of current ratings for BioCryst Pharmaceuticals and X4 Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioCryst Pharmaceuticals currently has a consensus target price of $8.00, suggesting a potential upside of 59.07%. X4 Pharmaceuticals has a consensus target price of $19.67, suggesting a potential upside of 125.28%. Given X4 Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than BioCryst Pharmaceuticals.
X4 Pharmaceuticals beats BioCryst Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonists of chemokine receptor CXCR4, which is in Phase I clinical trial to treat severe congenital neutropenia; Phase I/II clinical trial for the treatment of Waldenström macroglobulinemia; and Phase IIa clinical trial to treat clear cell renal cell carcinoma, as well as that has completed Phase II clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.